Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls

Johan Dicksved, Mathilda Lindberg, Magnus Rosenquist, Helena Enroth, Janet K. Jansson and Lars Engstrand

Correspondence
Lars Engstrand
lars.engstrand@smi.ki.se

Received 13 October 2008
Accepted 11 December 2008

Persistent infection of the gastric mucosa by Helicobacter pylori can initiate an inflammatory cascade that progresses into atrophic gastritis, a condition associated with reduced capacity for secretion of gastric acid and an increased risk of developing gastric cancer. The role of H. pylori as an initiator of inflammation is evident but the mechanism for development into gastric cancer has not yet been proven. A reduced capacity for gastric acid secretion allows survival and proliferation of other microbes that normally are killed by the acidic environment. It has been postulated that some of these species may be involved in the development of gastric cancer; however, their identities are poorly defined. In this study, the gastric microbiota from ten patients with gastric cancer was characterized and compared with that from five dyspeptic controls using the molecular profiling approach terminal restriction fragment length polymorphism (T-RFLP), in combination with 16S rRNA gene cloning and sequencing. T-RFLP analysis revealed a complex bacterial community in the cancer patients that was not significantly different from that in the controls. Sequencing of 140 clones revealed 102 phylotypes, with representatives from five bacterial phyla (Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and Fusobacteria). The data revealed a relatively low abundance of H. pylori and showed that the gastric cancer microbiota was instead dominated by different species of the genera Streptococcus, Lactobacillus, Veillonella and Prevotella. The respective role of these species in development of gastric cancer remains to be determined.

INTRODUCTION

Gastric cancer is a global health problem, with the highest rates in developing countries. Research during the past few decades has shown that Helicobacter pylori is the major causative agent in gastric cancer, although the aetiological mechanism is not yet fully understood. The majority of the individuals that are infected by H. pylori develop mild pangastritis, where the gastric physiology is maintained and not associated with disease (Smith et al., 2006). However, H. pylori infection can also lead to severe diseases. In antral predominant gastritis, the production of gastric acid is increased (hyperchlorhydria), which is associated with a high risk of development of duodenal ulcer disease, but protective against gastric cancer development (Hansson et al., 1996). By contrast, corpus predominant gastritis leads to lower production of gastric acid (hypochlorhydria) and may lead to atrophic gastritis, a condition with increased risk of developing gastric cancer (Uemura et al., 2001). The hypochlorhydric condition creates an environment suitable for other micro-organisms that can enter and colonize the stomach. Some of these bacteria are nitrogen-reducing bacteria that are able to produce carcinogenic N-nitroso compounds through conversion of nitrates or nitrites from

Abbreviations: T-RFLP, terminal restriction fragment length polymorphism; TRF, terminal restriction fragment.

The GenBank/EMBL/DDBJ accession numbers for the unique sequences generated in this study are FJ268879–FJ268953.
Table 1. Clinical characteristics for gastric cancer patients and dyspeptic controls

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Age (years)</th>
<th>Gender</th>
<th>Group</th>
<th>H. pylori culture</th>
<th>H. pylori serology</th>
<th>H. pylori total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ELISA</td>
<td>imm</td>
</tr>
<tr>
<td>1</td>
<td>88</td>
<td>M</td>
<td>Cancer</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>52</td>
<td>M</td>
<td>Cancer</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>58</td>
<td>M</td>
<td>Cancer</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>66</td>
<td>F</td>
<td>Cancer</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>67</td>
<td>M</td>
<td>Cancer</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>77</td>
<td>M</td>
<td>Cancer</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>73</td>
<td>M</td>
<td>Cancer</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>77</td>
<td>M</td>
<td>Cancer</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>77</td>
<td>F</td>
<td>Cancer</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>72</td>
<td>M</td>
<td>Cancer</td>
<td>1</td>
<td>ND*</td>
<td>1</td>
</tr>
<tr>
<td>C11</td>
<td>68</td>
<td>M</td>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C12</td>
<td>75</td>
<td>M</td>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C13</td>
<td>75</td>
<td>M</td>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C14</td>
<td>73</td>
<td>F</td>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C15</td>
<td>75</td>
<td>F</td>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*ND, Not determined.

The clinical material in this study was derived from a hospital-based study described previously (Enroth et al., 2000). Stomach biopsies from ten patients with non-cardia gastric cancer (five with intestinal type and five with diffuse type) and five dyspeptic control patients with normal gastric mucosal morphology were included in this study. Biopsies derived from non-cancerous gastric mucosa of antrum and corpus were pooled together. All subjects were included after providing informed consent, and the study was approved by the ethics committee of the Medical Faculty, Uppsala University DNR UU96/95 (Uppsala, Sweden). None of the individuals included in this study had taken antibiotics 5 years prior to sampling. Eight out of ten cancer patients were positive for H. pylori by one or more of four tests: culturing, immunohistochemistry, ELISA and immunoblotting (Enroth et al., 2000). However, only three of the patients (patients designated 2, 7 and 10) were positive for H. pylori by culturing alone. None of the controls were positive for H. pylori in any of the above-mentioned tests. Information about sociodemographic and clinical characteristics can be found in Table 1.

**METHODS**

**Patient cohort.** The clinical material in this study was derived from a hospital-based study described previously (Enroth et al., 2000). Stomach biopsies from ten patients with non-cardia gastric cancer (five with intestinal type and five with diffuse type) and five dyspeptic control patients with normal gastric mucosal morphology were included in this study. Biopsies derived from non-cancerous gastric mucosa of antrum and corpus were pooled together. All subjects were included after providing informed consent, and the study was approved by the ethics committee of the Medical Faculty, Uppsala University DNR UU96/95 (Uppsala, Sweden). None of the individuals included in this study had taken antibiotics 5 years prior to sampling. Eight out of ten cancer patients were positive for H. pylori by one or more of four tests: culturing, immunohistochemistry, ELISA and immunoblotting (Enroth et al., 2000). However, only three of the patients (patients designated 2, 7 and 10) were positive for H. pylori by culturing alone. None of the controls were positive for H. pylori in any of the above-mentioned tests. Information about sociodemographic and clinical characteristics can be found in Table 1.

**DNA isolation and PCR conditions.** Biopsies from antrum and corpus were homogenized together and stored in a freezing buffer containing glycerol at −70 °C. One hundred microlitres of the homogenized suspension was transferred to a microcentrifuge tube containing 0.25 ml of 0.1 mm zirconium beads with 180 µl ATL lysis buffer solution (Qiagen). In addition, 20 µl proteinase K was added to the tube. The bacterial cells in the samples were lysed by bead beating twice for 45 s at a setting of 5.0 using a FastPrep Instrument (MP Biomedicals). The DNA from the samples was then recovered using cloning and sequencing of 16S rRNA genes to assess the composition of the gastric microbiota of subjects with gastric cancer. The aim was to describe the composition of the gastric microbiota in patients with gastric cancer and compare it with that in subjects with normal gastric mucosal morphology.
the QIAamp DNA Mini kit (Qiagen) according to the manufacturer’s instructions for tissue samples, starting at step 3 in the protocol.

16S rRNA genes were amplified from the isolated DNA in three technical replicates per sample using the broad-range bacterial primers Bact 8F (5’-AGAGTTTGATCCTGGCTCAG-3’; Edwards et al., 1989), 5’-end-labelled with 6-carboxyfluorescein (6-FAM), and 926r (5’-CGGYCAATTCCCTTRAGTTT-3’; Muyzer et al., 1993). Amplification was carried out in 25 μl reaction mixtures under conditions that have been described previously (Dicksved et al., 2007), with the exception that the number of PCR cycles was increased to 35 instead of 30. PCR-amplified DNA product amounts and sizes were confirmed by agarose gel electrophoresis using GeneRuler 100 bp DNA ladder Plus (Fermentas Life Sciences) as a size marker.

**T-RFLP.** PCR products were digested with the HaeIII restriction enzyme (GE Healthcare) and the digested fragments were separated on an ABI 3700 capillary sequencer, as previously described (Hjort et al., 2007). The sizes of the fluorescently labelled fragments were determined by comparison with the internal GS ROX-500 size standard [Applied Biosystems (ABI)]. T-RFLP electropherograms were imaged using GENESCAN software (ABI). Relative peak areas of each terminal restriction fragment (TRF) were determined by dividing the area of the peak of interest by the total area of peaks within the following threshold values: lower threshold at 50 bp and upper threshold at 500 bp. A threshold for relative abundance was applied at 0.5% and only TRFs with higher relative abundances were included in the remaining analyses.

**Cloning and sequencing.** Cloning and sequencing of 16S rRNA genes that were PCR-amplified from DNA extracted from the biopsy samples was performed to confirm the identities of bacterial species corresponding to the dominant TRFs. DNA samples from six cancer patients (nos 4, 5, 6, 7, 8, and 9) were selected for amplification with the general primers Bact 8F and 926r. Three replicate PCR products from each individual were pooled and gel-purified using the Qiagen gel extraction kit. The pooled PCR products were cloned into the TOPO TA pCR 4.0 vector, followed by transformation into Escherichia coli TOP 10 competent cells (Invitrogen). A total of 64 inserts from each library were amplified using vector primers M13f and M13r (Invitrogen) with the same thermal cycling program as for T-RFLP analysis. The PCR products were digested with HaeIII and HinfI (GE Healthcare) and digested fragments were separated in a 2.5% agarose gel. Band patterns, i.e. restriction fragment length polymorphism (RFLP) types, were analysed using GelCompare software (Applied Maths). Plasmids from all clones with unique RFLP types and several redundant RFLP types were purified and selected prior to sequence analysis; in total 140 clones. Obtained sequences were examined using MacVector 8.1.1 (Accelrys Software) to identify their corresponding TRF sizes and for removal of redundant sequences. The remaining sequences were aligned against GenBank database entries using standard nucleotide BLAST at NCBI (www.ncbi.nlm.nih.gov). Hits defined as unknown or uncultured bacteria were subsequently aligned against sequenced bacterial genomes (genomic BLAST at NCBI), as well as examined with the Ribosomal Database Project II Sequence Match, in an attempt to classify them. Sequences with 99–100% similarity were given the same name as the species hit whereas sequences with 97–99% identity were assigned the genus name followed by ‘sp.’. Sequences were aligned online using MAFFT aligner version 6 with the Q-INS-i strategy (Katoh & Toh, 2008). A phylogenetic tree was constructed using PHYML v.2.4.5 (Guindon & Gascuel, 2003), and displayed using Figtree v1.0 (http://tree.bio.ed.ac.uk/software/figtree/), where large clusters were collapsed.

**Statistical analysis.** T-RFLP data from each individual were entered into a data matrix that consisted of the TRFs as variables and individuals as objects. A consensus T-RFLP profile was constructed for each of the technical duplicates. For significance testing of TRF distribution between the cancer patients and the controls, multi-response permutation procedures were used with Bray–Curtis metrics as distances measure (PC-ORD; MJM Software). Cluster analysis was based on Bray–Curtis distances and a dendrogram was created using the software PAST (http://folk.uio.no/ohammer/past/). Diversity, defined as evenness and richness of the bacterial community members detected as TRFs by T-RFLP analysis, was calculated using Simpson’s index of diversity (D) (Begon et al., 2006). Differences in TRF abundances between groups were tested using the Mann–Whitney test and P-values <0.05 were considered statistically significant.

**RESULTS AND DISCUSSION**

The inhospitable acidic milieu in the stomach provides an effective barrier, killing many of the microbes that enter the gastrointestinal tract. However, a change of the physiological conditions of the stomach, as occurs during acid-reducing drug therapy, corpus atrophy or gastric cancer, provides an opportunity for foreign microbes to enter and colonize the stomach. The evidence chain that targets *H. pylori* as a causative agent in gastric cancer development is long, but proof of the progression into cancer is lacking. Eradication of *H. pylori* was recently shown to decrease the incidence of gastric cancer (Fukase et al., 2008); however, the prophylactic effect of such eradication remains controversial (Malferttheiner et al., 2006). Duodenal ulcer disease, with overproduction of gastric acid, has been shown to protect against development of gastric cancer (Hansson et al., 1996). By contrast, several studies have suggested that an altered gastric physiology, as in corpus predominant gastritis, promotes bacterial overgrowth of the stomach and survival of potential genotoxic species with an unknown impact on human health (Calmels et al., 1987; Heavey & Rowland, 2004). However, current knowledge of the identities of these microbial immigrants has been biased by the inability to cultivate a large fraction of the gut microbiota. Therefore, we used molecular approaches in this study to describe the gastric microbiota of patients suffering from gastric cancer.

**Analysis of clone libraries**

Clone libraries were generated from six cancer patients, and a total of 384 clones were screened for their individual RFLP types. Each RFLP type was expected to originate from similar target sequences. Therefore, to reduce the number of clones to sequence for each group, all unique and redundant RFLP types were selected for sequencing. Out of the 140 clones sequenced, 102 phylotypes were found. These clustered into five bacterial phyla: *Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria* and *Fusobacteria* (Fig. 1). Members of the *Firmicutes* were most highly represented, with the majority corresponding to *Streptococcus, Lactobacillus* and different *Clostridiales*, such as *Veillonella*. The phylum *Bacteroidetes* was mainly represented by different species of *Prevotella*. All five classes of the *Proteobacteria* (*Alpha-, Beta-, Gamma-, Delta- and Epsilonproteobacteria*) were found in the clone libraries, with *Neisseria* and...
Haemophilus as the most dominant genera. *H. pylori* was only found in one of the libraries (no. 7), which was in concordance with previous culture-based results from this material (Table 1). In addition, members of the Actinobacteria and Fusobacteria were found, but clones corresponding to these phyla were not abundant.

**Correlation of clones to TRFs**

The TRF sizes of the sequenced clones were calculated *in silico* for their predicted lengths (base pairs) upon cleavage with the *Hae*III enzyme. Positive correlations between sequenced clones and TRFs were judged based on the presence of both a TRF and a clone with the same TRF size (base pairs) in the same samples. Most of the TRFs could be correlated with the sequence data (Fig. 2). For many of the TRFs, only one genus matched with the particular fragment size, but a few TRFs had several genera that matched, e.g. TRFs 64, 205, 271 and 331. The most dominant TRFs, found in the majority of the individuals, were related to *Streptococcus* sp. (TRFs 307, 309 and 317), *Prevotella* (TRF 264), *Veillonella* (TRF 212) and different Proteobacteria (TRF 205) (Fig. 2). For some TRFs, mainly rare ones with abundances lower than 5%, no matching sequences could be found in the libraries. In addition, some of the species found in the clone libraries had the restriction site outside the T-RFLP length-threshold values. This was the case for some members of the Proteobacteria, such as *Klebsiella pneumoniae*. By correlating TRFs to the sequence data, we found that the abundance of TRFs corresponding to *Firmicutes* represented 60% of the total population, followed by *Bacteroidetes* and *Actinobacteria* with relative abundances of 11% and 7%, respectively (Fig. 3). TRFs that correlated with *Proteobacteria* and *Fusobacteria* were present in lower abundances: 6% and 3%, respectively (Fig. 3). Approximately 12% of the T-RFLP abundance data could not be correlated with any sequence data (Fig. 3). This problem was mainly encountered for TRFs with low relative abundances, and many of the corresponding clones would probably have been found if more clones were sequenced. However, clones identified as *Prevotella multiformis* could be correlated with two different TRFs (177 and 264) possibly due to variations in the 16S rRNA gene sequences within this species.

**Analysis of the T-RFLP profiles**

The approach that we used in this study did not enable us to determine whether there were any differences in total abundances of bacteria between the cancer patients and the controls, but we could determine differences in relative abundances of some phyla. Analysis of the T-RFLP data revealed a total of 49 distinct TRFs and the mean number of TRFs found in an individual was 14 (range 7–20). None of the TRFs were present in all individuals and none were common for all cancer patients (Fig. 2). The diversity of
the microbiota was estimated based on the T-RFLP data using Simpson’s index of diversity. There were no significant differences in diversity indices between the cancer patients and the control group. When the samples were clustered according to their TRF patterns, four out of five healthy controls clustered together (Fig. 3), suggesting that these bacterial communities are more similar to each other than to those of the cancer patients. In addition, three of the cancer patients differed significantly ($P=0.001$) in their TRF distribution compared with the others (nos 5, 6 and 10; Fig. 2). In particular, the TRFs that corresponded to streptococci (274, 307, 309 and 317) were absent or very low in these three cancer patients. There was, however, no significant difference in the TRF distribution between all cancer patients and the healthy controls ($P=0.12$) tested with multiresponse permutation procedures.

Fig. 2. Relative abundances of terminal restriction fragments (TRFs) corresponding to dominant bacterial populations in the stomach of gastric cancer patients and controls with a normal gastric mucosa. The explanation of the relative abundance intervals is shown in a progressive grey scale with higher abundances correlating with darker shades. The abundance profile for each sample is represented in a column and the abundance for each TRF in a row. To reduce space in the figure, TRFs that were only present in one of the samples and not correlated with sequence data were removed. The samples were sorted according to their clustering with the Bray–Curtis index as distance matrix and using the UPGMA method for the dendrogram. Branches in black represent gastric cancer patients and those in grey represent controls. *Samples that were selected for clone library construction and sequencing of the 16S rRNA genes (see Fig. 1). Sequences from the 16S rRNA gene clone library having matching TRF sizes when digested with *HaeIII* in silico and their closest BLAST hits are shown to the left of their corresponding TRF.
suggesting that H. pylori methods (Bik negative based on traditional culturing or serological
H. pylori were created from six cancer patients and we only detected
H. pylori was detected in subjects that were considered
1995). In a previous study, based on molecular approaches,
hypochlorhydric stomachs (Houben & Stockbrügger,
in agreement with what has previously been reported in
study was very low. The TRF (271) that corresponds to
The abundance of
H. pylori
unique for
H. pylori
is
H. pylori
was in agreement with what has previously been reported in
H. pylori was detected in subjects that were considered
H. pylori was absent in the other five
H. pylori was in the one patient that was positive by culture,
suggesting that H. pylori was absent in the other five
individuals. However, only a limited number of clones
were screened from each library and it is possible that we
would have found H. pylori clones in these libraries by
increasing the number of sequenced clones. Nevertheless,
our results demonstrate a high microbial diversity in the
stomach and are in accordance with a recent cloning survey
of the stomach microbiota in hospitalized individuals (Bik et al., 2006).
In our study, clone libraries
were created from six cancer patients and we only detected
H. pylori in the one patient that was positive by culture,
suggesting that H. pylori was absent in the other five
individuals. However, only a limited number of clones
were screened from each library and it is possible that we
would have found H. pylori clones in these libraries by
increasing the number of sequenced clones. Nevertheless,
our results demonstrate a high microbial diversity in the
stomach and are in accordance with a recent cloning survey
of the stomach microbiota in hospitalized individuals (Bik et al., 2006), although the previous study did not include
gastric cancer patients. The main difference in bacterial
composition between this study and the study of Bik et al. (2006) was an overall lower prevalence of H. pylori and
higher prevalence of clones or TRFs matching with lactobacilli in this study.

Abundance of H. pylori

The abundance of H. pylori in all samples included in this
study was very low. The TRF (271) that corresponds to H. pylori was not among the most abundant ones and is not
unique for H. pylori. The low abundance of H. pylori is
in agreement with what has previously been reported in
hypochlorhydric stomachs (Houben & Stockbrügger, 1995). In a previous study, based on molecular approaches,
H. pylori was detected in subjects that were considered
negative based on traditional culturing or serological
methods (Bik et al., 2006). In our study, clone libraries
were created from six cancer patients and we only detected
H. pylori in the one patient that was positive by culture,
suggesting that H. pylori was absent in the other five
individuals. However, only a limited number of clones
were screened from each library and it is possible that we
would have found H. pylori clones in these libraries by
increasing the number of sequenced clones. Nevertheless,
our results demonstrate a high microbial diversity in the
stomach and are in accordance with a recent cloning survey
of the stomach microbiota in hospitalized individuals (Bik et al., 2006), although the previous study did not include
gastric cancer patients. The main difference in bacterial
composition between this study and the study of Bik et al. (2006) was an overall lower prevalence of H. pylori and
higher prevalence of clones or TRFs matching with lactobacilli in this study.

Presence of Streptococcus bovis, a bacterium
associated with colorectal cancer

It has previously been shown that bacteria more frequently
colonize gastric tumours compared to the surrounding
mucosal tissues, and the most frequent colonizers of
tumours are Gram-positive cocci such as streptococci
(Sjöstedt et al., 1988). Streptococci are commonly isolated
from the stomach and they have a wide repertoire of
clinical features that can affect the host. For example,
among the clones in this study, we found some that
corresponded to S. bovis, a species that has been associated
with colorectal cancer (Biarc et al., 2004; Ellmerich et al.,
2000). It has been demonstrated that S. bovis or its antigens
can promote cancer in rats, and that it exerted its
pathological activity in the colonic mucosa only when
pre-neoplastic lesions were established (Biarc et al., 2004).
As for CagA-positive strains of H. pylori, S. bovis or its
wall-extracted antigens can induce an overexpression of
inflammatory mediators known to be associated with
carcinogenesis, such as IL-8, prostaglandin E2 (PGE2)
and cyclooxygenase (COX-2) (Jüttner et al., 2003).
Further analysis of this group of bacteria is warranted to
elucidate their potential involvement in gastric cancer
progression.

Acid-reducing therapy

The control group in this study was hospital-based, and the
individuals were relatively old, with a possible deficiency in
acid production that may have influenced the results.
Unfortunately, the pH of the gastric juice was not
measured in the individuals partaking in this study. In
hypochlorhydric stomachs, more bacteria may be in an
actively growing state because of the more favourable pH.
This hypothesis is supported by previous investigations on
persons that have taken acid-reducing drugs where a higher
microbial diversity than normal was detected, and a
correlation was found to species normally found in the
oro-pharyngeal tract (Adamsson et al., 1999; Mowat et al.,
2000). The microbial species composition found in the
stomach during acid-reducing drug therapy shares many
similarities with that found in the stomach of gastric cancer
patients. This emphasizes the need for further research to
characterize the structure and the activity of the microbiota
in gastric cancer patients as well as in individuals
undergoing acid-reducing drug therapy.

N-Nitroso compounds and gastric cancer

Another factor that is thought to be a risk factor in
developing gastric cancer is formation of N-nitroso com-
ponents. Correa (1992) postulated that bacteria present in the
hypochlorhydric stomach have the ability to reduce dietary
nitrate to nitrite, and subsequently produce carcinogenic N-
nitroso compounds using secondary amines from food
(Correa, 1992). It has also been reported that some of the
species commonly found in the oral cavity have the ability
to promote these reactions (Calmels et al., 1987; Ziebarth et al.,
1997). In this study, several of the clones identified are
normally found in the oral cavity, and may be potent
promoters of this reaction, although this requires further
investigation to confirm.
Conclusion

In the current study, the gastric microbiota of patients with gastric cancer was characterized for the first time using molecular approaches and compared with that of dyspeptic controls having a normal healthy mucosa. Representatives of several genera were detected with a predominance of Firmicutes, mainly of oral origin. However, no significant differences in microbial compositions were found between cancer patients and controls. The prevalence of *H. pylori* was very low and this bacterium was only found in samples where it had previously been isolated using culture-based techniques. Although we only examined a limited number of subjects, this study contributes the first DNA-based description of the bacterial community composition in the stomachs of individuals with gastric cancer and shows the presence of a complex gastric microbiota with potential as a maintainer or bystander in the progression of gastric cancer.

ACKNOWLEDGEMENTS

This work was supported by the Uppsala BioX project, MICPROF, the Swedish Cancer Foundation, project 4518-B06-07, and in part by the US Department of Energy, Contract DE-AC02-05CH11231 with Lawrence Berkeley National Laboratory.

REFERENCES


